Patrick Deegan

List of Publications by Year
in descending order

19	768	933447 10	839539 18
papers	citations	h-index	g-index

19	19	19	1225
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Improving the quantitative classification of Erlenmeyer flask deformities. Skeletal Radiology, 2021, 50, 361-369.	2.0	3
2	The International Collaborative Gaucher Group GRAF (Gaucher Risk Assessment for Fracture) score: a composite risk score for assessing adult fracture risk in imiglucerase-treated Gaucher disease type 1 patients. Orphanet Journal of Rare Diseases, 2021, 16, 92.	2.7	5
3	In-depth phenotyping for clinical stratification of Gaucher disease. Orphanet Journal of Rare Diseases, 2021, 16, 431.	2.7	11
4	MO035HISTORICAL CONTROL ANALYSIS DEMONSTRATES SUPERIOR REDUCTION OF PLASMA GLOBOTRIAOSYLCERAMIDE BY VENGLUSTAT COMPARED WITH PLACEBO OR AGALSIDASE BETA IN CLASSIC FABRY DISEASE PATIENTS. Nephrology Dialysis Transplantation, 2020, 35, .	0.7	2
5	P0062GLUCOSYLCERAMIDE SYNTHASE INHIBITION WITH VENGLUSTAT IN CLASSIC FABRY DISEASE PATIENTS LEADS TO PROGRESSIVE REDUCTION OF ENDOTHELIAL CELL GLOBOTRIAOSYLCERAMIDE INCLUSION VOLUME. Nephrology Dialysis Transplantation, 2020, 35, .	0.7	1
6	Gaucher Disease in Bone: From Pathophysiology to Practice. Journal of Bone and Mineral Research, 2019, 34, 996-1013.	2.8	94
7	A randomised controlled trial evaluating arrhythmia burden, risk of sudden cardiac death and stroke in patients with Fabry disease: the role of implantable loop recorders (RaILRoAD) compared with current standard practice. Trials, 2019, 20, 314.	1.6	6
8	Study of indications for cardiac device implantation and utilisation in Fabry cardiomyopathy. Heart, 2019, 105, 1825-1831.	2.9	15
9	Characteristics of 26 patients with type 3 Gaucher disease: A descriptive analysis from the Gaucher Outcome Survey. Molecular Genetics and Metabolism Reports, 2018, 14, 73-79.	1.1	18
10	Reported outcomes of 453 pregnancies in patients with Gaucher disease: An analysis from the Gaucher outcome survey. Blood Cells, Molecules, and Diseases, 2018, 68, 226-231.	1.4	20
11	Demographics and patient characteristics of 1209 patients with Gaucher disease: Descriptive analysis from the Gaucher Outcome Survey (GOS). American Journal of Hematology, 2018, 93, 205-212.	4.1	44
12	The motor and cognitive features of Parkinsonâ€™s disease in patients with concurrent Gaucher disease over 2 years: a case series. Journal of Neurology, 2018, 265, 1789-1794.	3.6	11
13	Healthcare resource use and costs of managing children and adults with lysosomal acid lipase deficiency at a tertiary referral centre in the United Kingdom. PLoS ONE, 2018, 13, e0191945.	2.5	4
14	Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study. Journal of Medical Genetics, 2017, 54, 288-296.	3.2	262
15	Exploring the patient journey to diagnosis of Gaucher disease from the perspective of 212 patients with Gaucher disease and 16 Gaucher expert physicians. Molecular Genetics and Metabolism, 2017, 122, 122-129.	1.1	51
16	The glucocerobrosidase E326K variant predisposes to Parkinson's disease, but does not cause Gaucher's disease. Movement Disorders, 2013, 28, 232-236.	3.9	121
17	Determinants of Persisting Thrombocytopenia In Patients with Type 1 Gaucher Disease Treated with Alglucerase/Imiglucerase for 4â€“5 Years. Blood, 2010, 116, 4719-4719.	1.4	0
18	Timing of initiation of enzyme replacement therapy after diagnosis of type 1 Gaucher disease: effect on incidence of avascular necrosis. British Journal of Haematology, 2009, 147, 561-570.	2.5	97

#	Article	IF	Citations
19	Avascular Necrosis in Untreated Patients with Type 1 Gaucher Disease.. Blood, 2009, 114, 1353-1353.	1.4	3